Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
Status:
Completed
Trial end date:
2017-08-08
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, open-label study in patients with surgically incurable stage
III or IV uveal melanoma who have not received prior immunotherapy. CP-675,206 is thought to
stimulate patients' immune systems to attack their tumors. CP-675,206 has been shown to
induce durable tumor responses in patients with metastatic melanoma in phase 1 and phase 2
clinical studies.
Phase:
Phase 2
Details
Lead Sponsor:
AHS Cancer Control Alberta Alberta Health Services